The effect of pioglitazone in psoriasis

Not Applicable

• Conditions: psoriasis.; Plaque psoriasis

• Registration Number: IRCT201202279149N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

plaque type psoriasis; Indication for systemic therapy; Phototherapy contraindicated; No systemic therapy or phototherapy in last 6 months

Exclusion criteria: congestive heart failure; renal disease ; hepatic or pulmonary disease; abnormal hepatic enzymes; diabetes; pregnancy or lactation; potential for childbearing; any other major systemic diseases.

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Psoriasis area and severity index (PASI). Timepoint: at weeks 0, 6, 10, 16. Method of measurement: PASI meter.;Dermatology life quality index (DLQI). Timepoint: at weeks 0,6,10,16. Method of measurement: Questionnaire.

Secondary Outcome Measures

Name	Time	Method
Hepatic enzymes. Timepoint: at weeks 0, 1,2,4,6,10,16. Method of measurement: blood biochemistry.;Complete blood cells (CBC). Timepoint: at weeks 0,1,2,4,6,10,16. Method of measurement: automated analyzer (Automated blood count).;Lipid profile. Timepoint: at weeks, 0, 6,10, 16. Method of measurement: Lipid Blood Tests.;Bun and creatinine. Timepoint: at weeks 0,6,10,16. Method of measurement: blood biochemistry.;Urine analysis. Timepoint: at weeks 0,6,10,16. Method of measurement: Urine test strip.